Clinical Trials Browser

Phase 1/2 × INDUSTRY × Castrate-Resistant Prostate Cancer × Clear all

NCT01234025 2023-10-06

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Phase 1/2 Completed

Castrate-Resistant Prostate Cancer